Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology source : Www.zynerba.com save search
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
Published: 2022-03-22 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 1.54%
H: 5.81%
C: 4.55%
rare disease
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Published: 2022-02-28 (Crawled : 21:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.91%
H: 3.38%
C: -2.7%
als europe drug granted drug designation orphan drug grant syndros designation zygel
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-02-28 (Crawled : 13:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial syndros enroll zygel
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
Published: 2022-02-15 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.74%
H: 4.04%
C: 4.04%
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
|
| O: 0.65%
H: 6.41%
C: 4.49%
als ces
Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
Published: 2022-02-10 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 1.79%
H: 3.52%
C: 0.0%
health als thc conference svb leerink global
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
Published: 2022-01-06 (Crawled : 12:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -8.56%
H: 3.37%
C: 1.12%
als conference
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
Published: 2022-01-04 (Crawled : 22:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -3.63%
H: 0.0%
C: 0.0%
als lsd
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
Published: 2021-11-15 (Crawled : 12:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 2.94%
H: 0.0%
C: 0.0%
financial results results
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
Published: 2021-10-21 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 3.36%
C: 2.74%
presentation conference
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-19 (Crawled : 21:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 1.0%
C: 0.0%
presentation disease rare
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Published: 2021-09-13 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 1.9%
C: -0.45%
phase 3 trial syndros zygel
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
Published: 2021-09-09 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 7.64%
C: 5.32%
children conference zygel lsd
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open
Published: 2021-09-07 (Crawled : 11:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -1.11%
H: 3.14%
C: 0.0%
phase 2 results children zygel
Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
Published: 2021-09-02 (Crawled : 11:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.47%
H: 5.84%
C: 5.84%
presentation conference
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
Published: 2021-08-04 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -0.68%
H: 2.95%
C: -1.81%
growth conference
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
Published: 2021-06-30 (Crawled : 11:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -0.18%
H: 0.74%
C: -2.22%
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
Published: 2021-06-09 (Crawled : 20:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.18%
H: 0.36%
C: -3.04%
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Published: 2021-06-03 (Crawled : 14:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -1.7%
H: 6.72%
C: -0.58%
presentation children lsd
Notice of Settlement of Derivative Actions
Published: 2021-05-26 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -1.39%
H: 7.46%
C: 6.95%
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
Published: 2021-05-17 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -3.36%
H: 5.57%
C: 4.18%
presentation tcom research conference
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.